

Remarks

The current amendment cancels pending claims 17 to 20, amends claim 13 and adds new claims 21 to 22. The new claims have basis throughout the specification. For example, patients incapable of autoregulation of blood glucose are discussed on page 22, lines 10 to 20 (new claim 21). Buffers and preservatives are discussed on page 20, lines 5 to 13 (new claim 22). The amended claim and the new claims add no new matter.

Response to Obviousness-type Double Patenting Rejection

Although Applicant does not necessarily agree with the Examiner's double patenting rejections, Applicant has filed a terminal disclaimer over the '819 patent and the '006 patent to overcome this rejection.

Respectfully submitted,

/Mark J. Stewart/

Mark J. Stewart, Ph.D.
Attorney for Applicants
Registration No. 43,936
Phone: 317-276-0280

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

November 2, 2006